Discover our new oral solid dose (OSD) development capabilities at our Bend, Oregon site.
The journey from designing cell and gene therapies for research studies to manufacturing them in a cGMP environment and making them available to patients is costly, time-sensitive, and filled with numerous challenges. By partnering with an industry-leading CDMO that follows a “begin-with-the-end-in-mind” approach for translational research projects, you can reduce risk, accelerate development, and seamlessly transition to cGMP manufacturing, ultimately helping patients access life-changing therapies, faster. Download our fact sheet to learn more.